Korro Bio, Inc.

NASDAQ:KRRO

Biotechnology

Healthcare
$12.32 +15.88%

+$1.76 today

Market cap
$169.10M
Beta
2.10
P/E (TTM)
-1.3
EPS (TTM)
-$9.79
52W Low $5.20High $55.89

Volume 0.16M

Average 0.15M

KRRO Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Korro Bio, Inc.NASDAQ: KRRO

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin not reported for Q1 FY2026

What to watch

Whether operating margin reaches the consensus estimate from 6 analysts of -2649.3% for the fiscal year ending Dec 2026, down from -1366.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
-1366.4%+2680.7 pp YoY
LTMMar 2026
-2154.0%-173.6 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter—-9293.0 pp—
1 year+2680.7 pp-1282.9 pp-3963.5 pp
3 years—-1375.3 pp—
5 years+1172.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1366.4%
Year-over-year change
+2680.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How KRRO compares with its peers on the latest reported figures

  • KRRO's LTM Mar 2026 operating margin of -2154.0% is the 2nd highest of the 4 companies compared; the peer median is -9396.6%.
  • Its year-over-year change of -173.6 pp is the lowest of 3, against a peer median of +110887.6 pp.
KRRO Competitors Peer median
Operating Margin for KRRO and competitors
Company Period LTM level YoY 3-year change
AMRNAmarin Corporation plcLTM Mar 2026-17.4% +27.0 pp+22.2 pp
KRROKorro Bio, Inc.LTM Mar 2026-2154.0% -173.6 pp—
SLNSilence Therapeutics plcLTM Mar 2026-9396.6% —-15774.1 pp
ALTAltimmune, Inc.LTM Mar 2026-269216.7% +221748.3 pp-359490.4 pp
LBRXLB Pharmaceuticals Inc Common StockFY2025— ——
ANROAlto Neuroscience, Inc.FY2025— ——
AURAAura Biosciences, Inc.FY2025— ——
ANNXAnnexon, Inc.FY2025— ——
LRMRLarimar Therapeutics, Inc.FY2025— ——
DBVTDBV Technologies S.A.FY2025— ——
ENGNenGene Holdings Inc.FY2025— ——
Peer median (excluding KRRO) -9396.6%+110887.6 pp-15774.1 pp

Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue14.07M002.27M6.39M
Cost of Revenue3.84M0004.28M
Gross Profit10.23M002.27M2.11M
Gross Margin72.7%——100.0%33.0%
Research & Development59.32M42.2M57.25M63.64M65.58M
Selling, General & Admin34.93M16.8M36.54M30.55M28.16M
Operating Expenses94.26M59M84.53M94.18M89.45M
Depreciation & Amortization3.84M2.51M3.63M3.57M4.28M
EBITDA(80.07M)(56.49M)(80.9M)(88.35M)(83.06M)
EBITDA Margin-569.1%——-3890.1%-1299.5%
Operating Income(84.03M)(59M)(84.53M)(91.91M)(87.34M)
Operating Margin-597.3%——-4047.1%-1366.4%
Interest Income397K947K000
Interest Expense764K118K000
Other Income / Expenses(640K)976K3.39M8.47M(29.28M)
Income Before Tax(84.67M)(58.02M)(81.15M)(83.44M)(116.62M)
Pre-Tax Margin-601.9%——-3674.2%-1824.5%
Income Tax Expense15K10K27K141K637K
Net Income(84.69M)(58.03M)(81.17M)(83.58M)(117.26M)
Net Margin-602.0%——-3680.4%-1834.5%
EPS (Basic)(4.94)(227.58)(53.09)(9.37)(12.48)
EPS (Diluted)(4.94)(227.42)(53.08)(9.37)(12.48)
Weighted Avg Shares4.45M255K1.53M8.92M9.4M
Weighted Avg Shares (Diluted)4.45M255.17K1.53M8.92M9.4M

Korro Bio, Inc.

NASDAQ:KRRO

Intrinsic Alpha fair value

Locked

Current Price

$12.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.